PD-L1 and PD-1 IHC Testing for Solid Tumors

Comprehensive PD-L1 Menu for Clinical Testing and Pharma Research

NeoGenomics Laboratories is a leader in precision diagnostics and is at the forefront of PD-L1/PD-1 immunotherapy testing. PD-L1 testing is an immunohistochemical assay that detects the level and expression sites of PD-L1 protein. As a companion/complementary diagnostic for certain tumors and indications, it helps identify patients for treatments including KEYTRUDA®1, OPDIVO®2, TECENTRIQ®3 and IMFINZI™4. Our broad offering, depth of pathology expertise and experience in immuno-oncology testing make us an ideal partner for your clinical or research testing needs.

  • Experience – One of the first labs to offer PD-L1 testing
  • Expertise – Reported thousands of PD-L1 results
  • Clinical Trials – Supports over 100 immuno-oncology clinical projects

Advantages of PD-L1 Testing at NeoGenomics

  • Comprehensive clinical grade PD-L1 testing in one central location
  • Accurate and sensitive detection of PD-L1 expression
  • Robust reporting and analysis capabilities under the direction of expert pathologists
  • Pharma and Research Services to support immunotherapy drug development programs
  • Flexible ordering options and fast TATs

Ordering Options

PD-L1 IHC and PD-1 IHC can be ordered as stand-alone tests or in any combination with other IHC, FISH, or molecular tests offered. PD-L1 22C3 pharmDx IHC is also a standard component of solid tumor NeoTYPE™ Cancer Profiles, which offer multimethod analyses of broad or tumor-specific biomarker profiles.

Testing for Every Current PD-L1 IHC IVD Assay   

  Clone   Indication Manufacturer FDA-Approved Assay Type Therapy
22C3 NSCLC Dako1 Companion Dx KEYTRUDA® (pembrolizumab)
28-8 NSCLC Dako2 Complementary Dx OPDIVO® (nivolumab)
Melanoma Complementary Dx
SP142 Urothelial Carcinoma Ventana3 Complementary Dx TECENTRIQ® (atezolizumab)
NSCLC Complementary Dx
SP263 Urothelial Carcinoma Ventana4   Complementary Dx IMFINZITM  (durvalumab)

 

Dr. Albitar Speaks on PD-L1 Testing

 


Dr. Maher Albitar, NeoGenomics’ CMO and Director of R&D, delivered the talk “Comparison of PD-L1 Companion, Complementary and Laboratory Developed Tests with Molecular Profiling” at Immunotherapy World on January 18th, 2017.

Learn More

References 
  1. PD-L1 IHC 22C3 pharmDx [package insert]. Carpinteria, CA: Dako; P03951_04/SK00621-5/2016.10
  2. PDL1 IHC 28-8 pharmDx [package insert]. Carpinteria, CA: Dako; P04163_02/SK00521-5/2016.01
  3. PD-L1 SP142 Assay [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.;1016217US Rev A; 2016-10-21
  4. PD-L1 SP263 Assay [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.; 1014737US Rev A; 2017-04-21